New chemo cocktail aims to stop triple negative breast cancer from returning
NCT ID NCT05949021
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a combination of two chemotherapy drugs, liposomal doxorubicin and carboplatin, given after surgery to people with early-stage triple negative breast cancer. The goal is to see if this treatment can reduce the risk of the cancer coming back. The study involves 30 participants and is currently active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal doxorubicin and carboplatin (chemotherapy drugs)
What this could lead to
If successful, this could offer a more effective adjuvant chemotherapy option for early-stage triple negative breast cancer, potentially lowering the chance of cancer returning after surgery.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 30 participants, so results may not apply to all patients. Chemotherapy drugs like these can cause serious side effects, including heart damage and bone marrow suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
RWJBarnabas Health - Community Medical Center
Toms River, New Jersey, 08755, United States
-
RWJBarnabas Health - Monmouth Medical Center Southern Campus
Lakewood, New Jersey, 08701, United States
-
RWJBarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, 07112, United States
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08903, United States
-
RWJBarnabas Health - Trinitas hospital and Comprehensive Center
Elizabeth, New Jersey, 08755, United States
-
RWJBarnabas Health Jersey City Medical Center
Jersey City, New Jersey, 07302, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University Hospital-Newark
Newark, New Jersey, 07112, United States